Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs
Authors
Keywords
-
Journal
CELL DEATH AND DIFFERENTIATION
Volume 22, Issue 12, Pages 1946-1956
Publisher
Springer Nature
Online
2015-05-29
DOI
10.1038/cdd.2015.59
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PLK1 Phosphorylates PAX3-FOXO1, the Inhibition of Which Triggers Regression of Alveolar Rhabdomyosarcoma
- (2014) V. Thalhammer et al. CANCER RESEARCH
- Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
- (2014) B T Gjertsen et al. LEUKEMIA
- Manganese Superoxide Dismutase Regulates a Redox Cycle Within the Cell Cycle
- (2013) Ehab H. Sarsour et al. ANTIOXIDANTS & REDOX SIGNALING
- Pan-Mammalian Target of Rapamycin (mTOR) Inhibitor AZD8055 Primes Rhabdomyosarcoma Cells for ABT-737-induced Apoptosis by Down-regulating Mcl-1 Protein
- (2013) Ellen Preuss et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program
- (2013) Richard Gorlick et al. PEDIATRIC BLOOD & CANCER
- Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation
- (2013) F Rapino et al. Cell Death & Disease
- Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death
- (2013) J M Eichhorn et al. Cell Death & Disease
- Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft-tissue Sarcoma committee experience and rationale for current COG studies
- (2012) Suman Malempati et al. PEDIATRIC BLOOD & CANCER
- Bortezomib Primes Neuroblastoma Cells for TRAIL-Induced Apoptosis by Linking the Death Receptor to the Mitochondrial Pathway
- (2011) I. Naumann et al. CLINICAL CANCER RESEARCH
- SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction
- (2011) Hiroyuki Inuzuka et al. NATURE
- Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
- (2011) Ingrid E. Wertz et al. NATURE
- Phosphorylation of Mcl-1 by CDK1–cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest
- (2010) Margaret E Harley et al. EMBO JOURNAL
- Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
- (2010) Klaus Strebhardt NATURE REVIEWS DRUG DISCOVERY
- Targeting mitochondria for cancer therapy
- (2010) Simone Fulda et al. NATURE REVIEWS DRUG DISCOVERY
- BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
- (2009) D. Rudolph et al. CLINICAL CANCER RESEARCH
- Cyclin-Dependent Kinase 1-Mediated Bcl-xL/Bcl-2 Phosphorylation Acts as a Functional Link Coupling Mitotic Arrest and Apoptosis
- (2009) D. T. Terrano et al. MOLECULAR AND CELLULAR BIOLOGY
- Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas
- (2009) K. Hu et al. MOLECULAR CANCER THERAPEUTICS
- Targeting XIAP Bypasses Bcl-2-Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth In vitro and In vivo
- (2008) M. Vogler et al. CANCER RESEARCH
- Identification of the Major Phosphorylation Site in Bcl-xL Induced by Microtubule Inhibitors and Analysis of Its Functional Significance
- (2008) Meenakshi Upreti et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More